Hydralazine is used to treat high blood pressure (hypertension). It is also used to control high blood pressure in a mother during pregnancy (pre-eclampsia or eclampsia) or in emergency situations when blood pressure is extremely high (hypertensive crisis).
High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure can increase the risk of heart attacks and strokes.
Hydralazine works by relaxing the blood vessels and increasing the supply of blood and oxygen to the heart while reducing its workload.
Hydralazine is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not specifically included in product labeling, Hydralazine is used in certain patients with the following medical condition:
Congestive heart failure.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Adult: 40-50 mg daily in divided doses, increased according to response. Max: 200 mg/day.
Renal impairment: Reduce dose or prolong dosage interval.
Hepatic impairment: Reduce dose or prolong dosage interval.
Adult: 5-10 mg via slow IV inj, repeated if necessary after 20-30 min. Alternatively, as continuous IV, initial dose is 200-300 mcg/min.
Maintenance: 50-150 mcg/min.
How should I use Hydralazine?
Use Hydralazine injection as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Hydralazine injection is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Hydralazine injection at home, a health care provider will teach you how to use it. Be sure you understand how to use Hydralazine injection. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
Do not use Hydralazine injection if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
If you miss a dose of Hydralazine injection, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Hydralazine injection.
Uses of Hydralazine in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Use: Labeled Indications
Hypertension: Management of moderate to severe hypertension. Note: Not recommended for the initial treatment of hypertension (ACC/AHA [Whelton 2017])
Off Label Uses
Heart failure with reduced ejection fraction
Data from a randomized, double-blind trial comparing enalapril and Hydralazine plus isosorbide dinitrate in patients with chronic heart failure with reduced ejection fraction (HFrEF) support the use of Hydralazine (in combination with isosorbide dinitrate) in patients with intolerance to angiotensin-converting enzyme (ACE) inhibitor therapy.
A direct-acting vasodilator that is used as an antihypertensive agent. [PubChem]
Generic name: Hydralazine hydrochloride
Dosage form: Tablets
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2-4 days, increase to 25 mg four times daily for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg four times daily. For maintenance, adjust dosage to the lowest effective levels.
The incidence of toxic reactions, particularly the L.E. cell syndrome, is high in the group of patients receiving large doses of Hydralazine.
In a few resistant patients, up to 300 mg of Hydralazine daily may be required for a significant antihypertensive effect. In such cases, a lower dosage of Hydralazine combined with a thiazide and/or reserpine or a beta blocker may be considered. However, when combining therapy, individual titration is essential to ensure the lowest possible therapeutic dose of each drug.
Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered. Consider therapy modification
Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Monitor therapy
Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. Monitor therapy
Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Avoid combination
Dapoxetine: May enhance the orthostatic hypotensive effect of Hydralazine. Monitor therapy
Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents. Monitor therapy
Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Monitor therapy
Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. Monitor therapy
Levodopa-Containing Products: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Containing Products. Monitor therapy
Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. Monitor therapy
Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Hydralazine. Monitor therapy
Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Consider therapy modification
Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. Monitor therapy
Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
In addition to its needed effects, some unwanted effects may be caused by Hydralazine (the active ingredient contained in Hydralazine). In the event that any of these side effects do occur, they may require medical attention.
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking Hydralazine:
Arm, back, or jaw pain
chest pain or discomfort
chest tightness or heaviness
fast, pounding, or irregular heartbeat or pulse
shortness of breath
Black, tarry stools
blindness or vision changes
blisters on the skin
burning of the face or mouth
burning, crawling, itching, numbness, painful, prickling, "pins and needles", or tingling feelings
clumsiness or unsteadiness
difficult or labored breathing
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
fever and sore throat
general feeling of discomfort or illness or weakness
lower back or side pain
numbness, tingling, pain, or weakness in the hands or feet
painful or difficult urination
shakiness in the legs, arms, hands, or feet
skin rash or itching
swelling of the feet or lower legs
swollen, painful, or tender lymph glands in the neck, armpit, or groin
tightness in the chest
trembling or shaking of the hands or feet
ulcers, sores, or white spots in the mouth
unusual bleeding or bruising
unusual tiredness or weakness
weakness in hands or feet
upper right abdominal or stomach pain
yellow eyes and skin
If any of the following symptoms of overdose occur while taking Hydralazine, get emergency help immediately:
Symptoms of overdose:
Feeling of warmth
redness of the face, neck, arms, and occasionally, upper chest
Minor Side Effects
Some of the side effects that can occur with Hydralazine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
You should not use this medication if you are allergic to Hydralazine, or if you have coronary artery disease, or rheumatic heart disease affecting the mitral valve.
Before taking Hydralazine, tell your doctor if you have kidney disease, lupus, angina pectoris (chest pain), or if you have ever had a stroke.
While taking Hydralazine, avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.
Call your doctor at once if you have a serious side effect such as fast or pounding heartbeats, swelling, numbness or tingling, dark-colored urine, joint pain or swelling with fever, chest pain, weakness or tired feeling, and urinating less than usual or not at all.
To be sure this medication is helping your condition and is not causing harmful effects, your blood pressure will need to be checked often. You may also need occasional blood tests. Do not miss any scheduled appointments.
Keep using Hydralazine as directed, even if you feel well. High blood pressure often has no symptoms, so you may not know when your blood pressure is high. You may need to use blood pressure medication for the rest of your life.
Active ingredient matches for Hydralazine:
Unit description / dosage (Manufacturer)
Tablet; Oral; Hydralazine Hydrochloride 25 mg
Tablet; Oral; Hydralazine Hydrochloride 50 mg
Tablet; Oral; Hydralazine Hydrochloride 10 mg
Tablet; Oral; Hydralazine Hydrochloride 100 mg
Injectable; Injection; Hydralazine Hydrochloride 20 mg / ml
Hydralazine 20 mg/ml vial
Hydralazine 100 mg tablet
Hydralazine-HCTZ 50-50 mg capsule
HydrALAZINE HCl 100 mg tablet
Hydralazine-HCTZ 25-25 mg capsule
Hydralazine-HCTZ 100-50 mg capsule
HydrALAZINE HCl 50 mg tablet
Apresoline 50 mg tablet
HydrALAZINE HCl 25 mg tablet
HydrALAZINE HCl 10 mg tablet
Hydralazine 50 mg tablet
Hydralazine 25 mg tablet
Apo-Hydralazine 50 mg Tablet
Novo-Hylazin 50 mg Tablet
Apo-Hydralazine 25 mg Tablet
Hydralazine 10 mg tablet
Apo-Hydralazine 10 mg Tablet
Novo-Hylazin 10 mg Tablet
Hydralazine tablet 10 mg (Aa Pharma Inc (Canada))
Hydralazine tablet 25 mg (Aa Pharma Inc (Canada))
Hydralazine tablet 50 mg (Aa Pharma Inc (Canada))
Hydralazine tablet 25 mg/1 (Cardinal Health (US))
Hydralazine tablet 50 mg/1 (Cardinal Health (US))
List of Hydralazine substitutes (brand and generic names):
DTP/NCI. "hydralazine: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Hydralazine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Hydralazine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
There are no reviews yet. Be the first to write one!